An International Publisher for Academic and Scientific Journals
Author Login 
Scholars Journal of Applied Medical Sciences | Volume-7 | Issue 02
Dyslipidemia in Childhood Nephrotic Syndrome: Is It Really a Matter for Concern?
Prasanth KS, Geetha S, Susan Uthup
Published: Feb. 12, 2019 | 261 246
DOI: 10.36347/sjams.2019.v07i02.008
Pages: 454-457
Downloads
Abstract
Hyperlipidemia, an important characteristic of idiopathic nephrotic syndrome in children, is usually observed during the active phase of the disease and disappears with the resolution of proteinuria [1]. However, persisting lipid abnormalities during remission have been reported in a few studies and raise the question of the later development of atherosclerosis in this population We have done a prospective hospital based cohort Study in Childhood Nephrotic Syndrome (NS) with the aim of assessing the pattern of lipid profile during relapse and to compare the same after three months of starting treatment in steroid sensitive, frequent relapsing, steroid dependent and steroid resistant nephrotic syndrome in a tertiary care teaching hospital. Children with idiopathic nephrotic syndrome during relapse were categorized into 4 groups: infrequent relapsing nephrotic syndrome (IRNS), frequent relapsing nephrotic syndrome (FRNS ); steroid dependent nephrotic syndrome (SDNS ) and steroid resistant nephrotic syndrome (SRNS). The fasting venous blood samples were analyzed for the total cholesterol, triglycerides, high density lipoprotein – cholesterol, low density lipoprotein – cholesterol and very low density lipoprotein – cholesterol at entry point and after three months of starting steroids. Data was analyzed using ANOVA and paired t test for significance. Statistically significant (P < 0.05) drop in lipid profile on follow up was noted in all categories of nephrotic children except those with SRNS. Abnormal lipid profile (> 95th centile of normative data with which comparison was made) was persisting in SRNS as well as in FRNS and SDNS on follow up. In FRNS and SDNS, extended follow up is needed to ascertain the persistence of hyperlipidemia associated with multiple relapses and the need for lipid lowering therapy as recommended for SRNS.